Daiichi Sankyo Company, Limited (OTCMKTS:DSNKY) Short Interest Update

Daiichi Sankyo Company, Limited (OTCMKTS:DSNKY - Get Free Report) saw a large growth in short interest in May. As of May 31st, there was short interest totalling 64,600 shares, a growth of 119.0% from the May 15th total of 29,500 shares. Approximately 0.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 643,400 shares, the days-to-cover ratio is presently 0.1 days.

Daiichi Sankyo Price Performance

Shares of DSNKY traded down $0.60 during midday trading on Friday, hitting $24.60. The company's stock had a trading volume of 83,280 shares, compared to its average volume of 264,550. The company has a quick ratio of 2.11, a current ratio of 2.77 and a debt-to-equity ratio of 0.06. Daiichi Sankyo has a one year low of $20.92 and a one year high of $42.48. The stock has a market capitalization of $46.60 billion and a price-to-earnings ratio of 28.60. The company's fifty day simple moving average is $24.56 and its two-hundred day simple moving average is $25.73.

Daiichi Sankyo (OTCMKTS:DSNKY - Get Free Report) last released its earnings results on Friday, April 25th. The company reported $0.30 earnings per share (EPS) for the quarter. The firm had revenue of $3.40 billion for the quarter. Daiichi Sankyo had a return on equity of 14.53% and a net margin of 13.62%. As a group, equities analysts expect that Daiichi Sankyo will post 0.73 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, Nomura Securities upgraded shares of Daiichi Sankyo to a "strong-buy" rating in a research report on Friday, June 6th.

Daiichi Sankyo Company Profile

Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.